SCHEMBL4884915

SCHEMBL4884915

Cc1cc(C23CC4CC(CC(C4)C2)C3)c(O)c(S(=O)(=O)Nc2ccc(C#N)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 7/20 0.52
BRD4 O60885 1/20 0.43
MCL1 Q07820 1/20 0.43
KDM1A O60341 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
TSHR P16473 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
SLC22A12 Q96S37 1/20 0.38
IDH1 O75874 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
SGK1 O00141 1/20 0.36
CYP19A1 P11511 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
DRD3 P35462 1/20 0.36
HTR6 P50406 1/20 0.36
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895380 0.88 PGR (0.49) PGRBRD4MCL1KDM1ACA1
SCHEMBL4896573 0.87 PGR (0.49) PGRBRD4MCL1KDM1AALDH1A1
SCHEMBL4886491 0.85 SLC22A12 (0.45) PGRTSHRSLC22A12
SCHEMBL4885016 0.75 BRD4 (0.53) BRD4MCL1KDM1AALDH1A1GAA
SCHEMBL4897237 0.73 SLC22A12 (0.45) PGRSLC22A12
SCHEMBL4886499 0.73 ACLY (0.44) PGRALDH1A1SLC22A12
SCHEMBL4890237 0.73 MEN1 (0.33) ALDH1A1GAAGFERSMN1; SMN2
SCHEMBL4895370 0.73 KDM4E (0.41) ALDH1A1GAACA1CA2GFER
SCHEMBL4897107 0.71 CRHBP (0.46) MCL1ALDH1A1GAAIDH1SMN1; SMN2
SCHEMBL549445 0.69 MEN1 (0.43) ALDH1A1GAATSHRGFERSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US claimed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP claimed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS PGR 4193/4885BRD4 218/4885MCL1 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.